AdverseEvent.ai
This page presents data from the FDA Adverse Event Reporting System (FAERS) and the FDA-approved drug label. A report submitted to FAERS does not prove a drug caused the reported event. Always consult a healthcare provider about medications.

Alprazolam

benzodiazepine
Last updated: August 29, 2026
Preview tracking

Alprazolam is a medication, a benzodiazepine. According to the FDA-approved label, Alprazolam tablets are indicated for the: acute treatment of generalized anxiety disorder (GAD) in adults. treatment of panic disorder (PD), with or without agoraphobia in adults. Alprazolam is a benzodiazepine indicated for the: Acute treatment of generalized anxiety disorder in. FAERS contains 204,912 submissions naming this drug from 2001 through 2026; the top three reactions cited are drug ineffective, nausea, and fatigue.

Most-Reported Reactions

Counts of the reactions most often cited in FAERS submissions that named Alprazolam. Inclusion here does not establish causation - submitters describe what was observed, not what was confirmed. One submission can list several reactions, so the totals exceed the report count.

DRUG INEFFECTIVE 13,641 (6.7%) NAUSEA 13,088 (6.4%) FATIGUE 12,190 (5.9%) DRUG ABUSE 11,119 (5.4%) ANXIETY 10,314 (5.0%) HEADACHE 10,117 (4.9%) PAIN 9,969 (4.9%) TOXICITY TO VARIOUS AGENTS 9,058 (4.4%) DIARRHOEA 9,013 (4.4%) DYSPNOEA 8,435 (4.1%) DIZZINESS 8,011 (3.9%) COMPLETED SUICIDE 7,650 (3.7%) DEPRESSION 7,319 (3.6%) VOMITING 7,293 (3.6%) INSOMNIA 7,288 (3.6%)

Patient Demographics

Patient sex and age across the FAERS submissions that named Alprazolam. Percentages here are computed only from submissions where these fields were filled in - many leave them blank.

By Sex

Female Male Unknown

By Age Group

0-17 18-44 45-64 65+

Severity Outcomes

Severity flags recorded across the 204,912 FAERS submissions that named Alprazolam. Each bar shows the count of those reports carrying that flag. A single case can carry more than one (a hospitalization that became life-threatening, for example), so these bars are independent rates - they don't sum to 100%. Inclusion of a case under any flag does not establish that the drug caused the outcome.

DEATH 33,439 (16.3%) HOSPITALIZATION 65,646 (32.0%) LIFE-THREATENING 8,292 (4.0%) DISABLING 5,024 (2.5%)

Submissions Per Quarter

Quarterly count of FAERS submissions that named Alprazolam. Ups and downs on this chart can track prescribing volume, news cycles, or shifts in how reports get filed, rather than the drug becoming safer or more dangerous.

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

From the FDA-Approved Label

Excerpts from the official FDA-approved prescribing information for Alprazolam. This is the authoritative source on indications, warnings, and known adverse reactions.

Indications

1 INDICATIONS AND USAGE Alprazolam tablets are indicated for the: acute treatment of generalized anxiety disorder (GAD) in adults. treatment of panic disorder (PD), with or without agoraphobia in adults. Alprazolam is a benzodiazepine indicated for the: Acute treatment of generalized anxiety disorder in adults. ( 1 ) Treatment of panic disorder with or without agoraphobia in adults. ( 1 )

Adverse Reactions (from label)

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Risks from Concomitant Use with Opioids [see Warnings and Precautions (5.1) ] Abuse, Misuse, and Addiction [see Warnings and Precautions (5.2) ] Dependence and Withdrawal Reactions [see Warnings and Precautions (5.3) ] Effects on Driving and Operating Machinery [see Warnings and Precautions (5.4) ] Patients with Depression [see Warnings and Precautions (5.6) ] Neonatal Sedation and Withdrawal Syndrome [see Warnings and Precautions (5.8) ] Risks in Patients with Impaired Respiratory Function [see Warnings and Precautions (5.9) ] The most common adverse reactions reported in clinical trials for generalized anxiety disorder and panic disorder (incidence > 5% and at least twice that of placebo) include: impaired coordination, hypotension, dysarthria, and increased libido. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical tria...

FDA label effective date: 2025-01-03

Disclaimer

AdverseEvent.ai is not affiliated with the FDA. Adverse-event counts come from the FDA Adverse Event Reporting System (FAERS). Drug labels come from the FDA drug label dataset. A report submitted to FAERS does not prove a drug caused the reported event — always consult a healthcare provider about medications. This site is for informational purposes only and is not medical advice.